Literature DB >> 23149937

RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues.

Julian P Venables1, Jean-Philippe Brosseau, Gilles Gadea, Roscoe Klinck, Panagiotis Prinos, Jean-François Beaulieu, Elvy Lapointe, Mathieu Durand, Philippe Thibault, Karine Tremblay, François Rousset, Jamal Tazi, Sherif Abou Elela, Benoit Chabot.   

Abstract

Alternative splicing provides a critical and flexible layer of regulation intervening in many biological processes to regulate the diversity of proteins and impact cell phenotype. To identify alternative splicing differences that distinguish epithelial from mesenchymal tissues, we have investigated hundreds of cassette exons using a high-throughput reverse transcription-PCR (RT-PCR) platform. Extensive changes in splicing were noted between epithelial and mesenchymal tissues in both human colon and ovarian tissues, with many changes from mostly one splice variant to predominantly the other. Remarkably, many of the splicing differences that distinguish normal mesenchymal from normal epithelial tissues matched those that differentiate normal ovarian tissues from ovarian cancer. Furthermore, because splicing profiling could classify cancer cell lines according to their epithelial/mesenchymal characteristics, we used these cancer cell lines to identify regulators for these specific splicing signatures. By knocking down 78 potential splicing factors in five cell lines, we provide an extensive view of the complex regulatory landscape associated with the epithelial and mesenchymal states, thus revealing that RBFOX2 is an important driver of mesenchymal tissue-specific splicing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23149937      PMCID: PMC3554129          DOI: 10.1128/MCB.01174-12

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  53 in total

1.  Multiple and specific mRNA processing targets for the major human hnRNP proteins.

Authors:  Julian P Venables; Chu-Shin Koh; Ulrike Froehlich; Elvy Lapointe; Sonia Couture; Lyna Inkel; Anne Bramard; Eric R Paquet; Valérie Watier; Mathieu Durand; Jean-François Lucier; Julien Gervais-Bird; Karine Tremblay; Panagiotis Prinos; Roscoe Klinck; Sherif Abou Elela; Benoit Chabot
Journal:  Mol Cell Biol       Date:  2008-07-21       Impact factor: 4.272

2.  Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines.

Authors:  Maria S Pino; Michele Balsamo; Francesca Di Modugno; Marcella Mottolese; Massimo Alessio; Elisa Melucci; Michele Milella; David J McConkey; Ulrike Philippar; Frank B Gertler; Pier Giorgio Natali; Paola Nisticò
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

3.  Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity.

Authors:  Sebastian Oltean; Brian S Sorg; Todd Albrecht; Vivian I Bonano; Robert M Brazas; Mark W Dewhirst; Mariano A Garcia-Blanco
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-08       Impact factor: 11.205

4.  ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing.

Authors:  Claude C Warzecha; Trey K Sato; Behnam Nabet; John B Hogenesch; Russ P Carstens
Journal:  Mol Cell       Date:  2009-03-13       Impact factor: 17.970

Review 5.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Authors:  Kornelia Polyak; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2009-03-05       Impact factor: 60.716

6.  An RNA code for the FOX2 splicing regulator revealed by mapping RNA-protein interactions in stem cells.

Authors:  Gene W Yeo; Nicole G Coufal; Tiffany Y Liang; Grace E Peng; Xiang-Dong Fu; Fred H Gage
Journal:  Nat Struct Mol Biol       Date:  2009-01-11       Impact factor: 15.369

Review 7.  Coordinated protein sorting, targeting and distribution in polarized cells.

Authors:  Ira Mellman; W James Nelson
Journal:  Nat Rev Mol Cell Biol       Date:  2008-11       Impact factor: 94.444

8.  Identification of alternative splicing markers for breast cancer.

Authors:  Julian P Venables; Roscoe Klinck; Anne Bramard; Lyna Inkel; Geneviève Dufresne-Martin; ChuShin Koh; Julien Gervais-Bird; Elvy Lapointe; Ulrike Froehlich; Mathieu Durand; Daniel Gendron; Jean-Philippe Brosseau; Philippe Thibault; Jean-Francois Lucier; Karine Tremblay; Panagiotis Prinos; Raymund J Wellinger; Benoit Chabot; Claudine Rancourt; Sherif Abou Elela
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

Review 9.  E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer.

Authors:  Otto Schmalhofer; Simone Brabletz; Thomas Brabletz
Journal:  Cancer Metastasis Rev       Date:  2009-06       Impact factor: 9.264

Review 10.  EMT, the cytoskeleton, and cancer cell invasion.

Authors:  Mahmut Yilmaz; Gerhard Christofori
Journal:  Cancer Metastasis Rev       Date:  2009-06       Impact factor: 9.264

View more
  78 in total

1.  Rbfox Proteins Regulate Splicing as Part of a Large Multiprotein Complex LASR.

Authors:  Andrey Damianov; Yi Ying; Chia-Ho Lin; Ji-Ann Lee; Diana Tran; Ajay A Vashisht; Emad Bahrami-Samani; Yi Xing; Kelsey C Martin; James A Wohlschlegel; Douglas L Black
Journal:  Cell       Date:  2016-04-21       Impact factor: 41.582

2.  Activation-Dependent TRAF3 Exon 8 Alternative Splicing Is Controlled by CELF2 and hnRNP C Binding to an Upstream Intronic Element.

Authors:  Astrid-Solveig Schultz; Marco Preussner; Mario Bunse; Rotem Karni; Florian Heyd
Journal:  Mol Cell Biol       Date:  2017-03-17       Impact factor: 4.272

Review 3.  Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.

Authors:  Debanwita Roy Burman; Shalini Das; Rahul Bhattacharya; Chandrima Das
Journal:  Mol Biol Rep       Date:  2021-01-05       Impact factor: 2.316

Review 4.  Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes.

Authors:  A Sveen; S Kilpinen; A Ruusulehto; R A Lothe; R I Skotheim
Journal:  Oncogene       Date:  2015-08-24       Impact factor: 9.867

5.  Genomic HEXploring allows landscaping of novel potential splicing regulatory elements.

Authors:  Steffen Erkelenz; Stephan Theiss; Marianne Otte; Marek Widera; Jan Otto Peter; Heiner Schaal
Journal:  Nucleic Acids Res       Date:  2014-08-21       Impact factor: 16.971

6.  Dysregulation of RBFOX2 Is an Early Event in Cardiac Pathogenesis of Diabetes.

Authors:  Curtis A Nutter; Elizabeth A Jaworski; Sunil K Verma; Vaibhav Deshmukh; Qiongling Wang; Olga B Botvinnik; Mario J Lozano; Ismail J Abass; Talha Ijaz; Allan R Brasier; Nisha J Garg; Xander H T Wehrens; Gene W Yeo; Muge N Kuyumcu-Martinez
Journal:  Cell Rep       Date:  2016-05-26       Impact factor: 9.423

Review 7.  Developmental regulation of RNA processing by Rbfox proteins.

Authors:  John G Conboy
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-10-17       Impact factor: 9.957

8.  Single-Cell RNA Sequencing Reveals mRNA Splice Isoform Switching during Kidney Development.

Authors:  Yishay Wineberg; Tali Hana Bar-Lev; Anna Futorian; Nissim Ben-Haim; Leah Armon; Debby Ickowicz; Sarit Oriel; Efrat Bucris; Yishai Yehuda; Naomi Pode-Shakked; Shlomit Gilad; Sima Benjamin; Peter Hohenstein; Benjamin Dekel; Achia Urbach; Tomer Kalisky
Journal:  J Am Soc Nephrol       Date:  2020-07-10       Impact factor: 10.121

Review 9.  TGF-beta signaling in cancer: post-transcriptional regulation of EMT via hnRNP E1.

Authors:  Breege V Howley; Philip H Howe
Journal:  Cytokine       Date:  2018-02-01       Impact factor: 3.861

10.  Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges.

Authors:  Michael T Lovci; Dana Ghanem; Henry Marr; Justin Arnold; Sherry Gee; Marilyn Parra; Tiffany Y Liang; Thomas J Stark; Lauren T Gehman; Shawn Hoon; Katlin B Massirer; Gabriel A Pratt; Douglas L Black; Joe W Gray; John G Conboy; Gene W Yeo
Journal:  Nat Struct Mol Biol       Date:  2013-11-10       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.